Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. filed a notice for the potential sale of its common stock by an affiliate. The filing covers 7,438 shares of common stock, to be sold through Merrill Lynch on July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless exercise. The covered shares have an aggregate market value of $199,884.80 based on the information provided.
The filing also lists a prior sale by Eric Warren of 104,124 shares of common stock on June 26, 2026 for total proceeds of $2,696,321.98 during the past three months.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold: 7,438 shares
Aggregate market value: $199,884.80
Past 3-month shares sold: 104,124 shares
+2 more
5 metrics
Shares to be sold
7,438 shares
Common stock covered for potential sale on July 21, 2026
Aggregate market value
$199,884.80
Value of 7,438 common shares covered by the new notice
Past 3-month shares sold
104,124 shares
Common stock sold on June 26, 2026
Past 3-month sale proceeds
$2,696,321.98
Proceeds from June 26, 2026 sale of 104,124 shares
Planned sale date
07/21/2026
Scheduled date for sale of 7,438 shares
Key Terms
Form 144, Exercise of employee stock options, Broker assisted cashless exercise
3 terms
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of employee stock options financial
"Exercise of employee stock options | Mineralys Therapeutics, Inc."
Broker assisted cashless exercise financial
"Broker assisted cashless exercise"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Mineralys Therapeutics (MLYS) disclose in this Form 144 filing?
Mineralys Therapeutics discloses a planned sale of 7,438 shares of common stock by an affiliate on July 21, 2026 after an employee stock option exercise, along with a previously completed sale during the last three months.
What prior Mineralys Therapeutics (MLYS) stock sale is disclosed for the past three months?
The filing reports that on June 26, 2026, 104,124 shares of Mineralys Therapeutics common stock were sold for total proceeds of $2,696,321.98. This transaction is listed as a sale during the past three months.
Who is the selling security holder in the recent MLYS Form 144 disclosure?
The filing identifies Eric Warren, with a Radnor, Pennsylvania address, as the related party. The document associates him with a June 26, 2026 sale of 104,124 common shares for $2,696,321.98 and the new notice to sell 7,438 shares.